This study shed new light on the underlying pathogenic mechanisms of podocyte injury in DKD and highlights the therapeutic potential of mitigating podocyte injury through inhibition of the RIPK3/NF‐κB p65‐mediated inflammatory response as a viable treatment option for DKD. This evidence concerns the gene RIPK3 and diabetic kidney disease.